Poniard Pharmaceuticals, Inc.
PARD
$0.0001
$0.000.00%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.86M | 3.40M | 2.90M | 4.68M | 5.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.15M | 3.84M | 3.23M | 3.50M | 5.95M |
| Operating Income | -3.15M | -3.84M | -3.23M | -3.50M | -5.95M |
| Income Before Tax | -3.77M | -3.86M | -3.25M | -5.17M | -6.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.77M | -3.86M | -3.25M | -5.17M | -6.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.77M | -3.86M | -3.25M | -5.17M | -6.45M |
| EBIT | -3.15M | -3.84M | -3.23M | -3.50M | -5.95M |
| EBITDA | -2.84M | -3.52M | -2.91M | -3.17M | -5.62M |
| EPS Basic | -2.55 | -2.62 | -2.44 | -4.31 | -5.39 |
| Normalized Basic EPS | -1.32 | -1.62 | -1.50 | -2.04 | -3.34 |
| EPS Diluted | -2.55 | -2.62 | -2.44 | -4.31 | -5.39 |
| Normalized Diluted EPS | -1.32 | -1.62 | -1.50 | -2.04 | -3.34 |
| Average Basic Shares Outstanding | 1.50M | 1.49M | 1.35M | 1.21M | 1.21M |
| Average Diluted Shares Outstanding | 1.50M | 1.49M | 1.35M | 1.21M | 1.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | -2.49% | -- | -1.86% | 0.00% |